Is WVE or ERAS more profitable?

Erasca has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Erasca's return on equity of -35.31% beat WAVE Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets WAVE Life Sciences -255.70% -56.76% -42.80% Erasca N/A -35.31% -29.49%

Does the media favor WVE or ERAS?

In the previous week, Erasca had 30 more articles in the media than WAVE Life Sciences. MarketBeat recorded 31 mentions for Erasca and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.50 beat Erasca's score of -0.01 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 2 Very Positive mention(s) 0 Positive mention(s) 27 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to TNGX or WVE?

In the previous week, Tango Therapeutics and Tango Therapeutics both had 1 articles in the media. WAVE Life Sciences' average media sentiment score of 0.50 beat Tango Therapeutics' score of 0.34 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNTH or WVE?

In the previous week, Dianthus Therapeutics had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 6 mentions for Dianthus Therapeutics and 1 mentions for WAVE Life Sciences. Dianthus Therapeutics' average media sentiment score of 0.53 beat WAVE Life Sciences' score of 0.50 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ORKA or WVE?

In the previous week, Oruka Therapeutics had 8 more articles in the media than WAVE Life Sciences. MarketBeat recorded 9 mentions for Oruka Therapeutics and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.50 beat Oruka Therapeutics' score of -0.06 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, WVE or MANE?

Veradermics has lower revenue, but higher earnings than WAVE Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio WAVE Life Sciences $42.73M 27.74 -$204.38M -$1.06 N/A Veradermics N/A N/A N/A N/A N/A

Does the media prefer WVE or MANE?

In the previous week, Veradermics had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Veradermics and 1 mentions for WAVE Life Sciences. Veradermics' average media sentiment score of 0.88 beat WAVE Life Sciences' score of 0.50 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

WAVE Life Sciences (WVE) Competitors

$6.16 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$6.15 -0.01 (-0.21%)

As of 06/18/2026 07:59 PM Eastern

Compare

WVE vs. ERAS, TNGX, DNTH, ORKA, and MANE

Should you buy WAVE Life Sciences stock or one of its competitors? MarketBeat compares WAVE Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with WAVE Life Sciences include Erasca (ERAS), Tango Therapeutics (TNGX), Dianthus Therapeutics (DNTH), Oruka Therapeutics (ORKA), and Veradermics (MANE). These companies are all part of the "pharmaceutical products" industry.

How does WAVE Life Sciences compare to Erasca?

WAVE Life Sciences (NASDAQ:WVE) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Erasca had 30 more articles in the media than WAVE Life Sciences. MarketBeat recorded 31 mentions for Erasca and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.50 beat Erasca's score of -0.01 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	2 Very Positive mention(s)	0 Positive mention(s)	27 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Erasca has lower revenue, but higher earnings than WAVE Life Sciences. Erasca is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	27.74	-$204.38M	-$1.06	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

WAVE Life Sciences has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market. Comparatively, Erasca has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Erasca has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Erasca's return on equity of -35.31% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Erasca	N/A	-35.31%	-29.49%

WAVE Life Sciences presently has a consensus price target of $26.41, indicating a potential upside of 328.76%. Erasca has a consensus price target of $20.11, indicating a potential upside of 47.12%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe WAVE Life Sciences is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

WAVE Life Sciences beats Erasca on 8 of the 15 factors compared between the two stocks.

How does WAVE Life Sciences compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Tango Therapeutics has higher revenue and earnings than WAVE Life Sciences. Tango Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	64.86	-$101.59M	-$0.83	N/A
WAVE Life Sciences	$42.73M	27.74	-$204.38M	-$1.06	N/A

In the previous week, Tango Therapeutics and Tango Therapeutics both had 1 articles in the media. WAVE Life Sciences' average media sentiment score of 0.50 beat Tango Therapeutics' score of 0.34 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the broader market.

Tango Therapeutics has a net margin of -151.15% compared to WAVE Life Sciences' net margin of -255.70%. Tango Therapeutics' return on equity of -41.54% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tango Therapeutics currently has a consensus target price of $38.42, indicating a potential upside of 37.35%. WAVE Life Sciences has a consensus target price of $26.41, indicating a potential upside of 328.76%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

Tango Therapeutics beats WAVE Life Sciences on 8 of the 15 factors compared between the two stocks.

How does WAVE Life Sciences compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

WAVE Life Sciences has a net margin of -255.70% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Dianthus Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,210.65	-$162.34M	-$4.13	N/A
WAVE Life Sciences	$42.73M	27.74	-$204.38M	-$1.06	N/A

Dianthus Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, suggesting that its share price is 233% less volatile than the broader market.

Dianthus Therapeutics currently has a consensus target price of $117.82, indicating a potential upside of 42.83%. WAVE Life Sciences has a consensus target price of $26.41, indicating a potential upside of 328.76%. Given WAVE Life Sciences' higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Dianthus Therapeutics had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 6 mentions for Dianthus Therapeutics and 1 mentions for WAVE Life Sciences. Dianthus Therapeutics' average media sentiment score of 0.53 beat WAVE Life Sciences' score of 0.50 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dianthus Therapeutics beats WAVE Life Sciences on 9 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oruka Therapeutics currently has a consensus price target of $131.30, suggesting a potential upside of 81.50%. WAVE Life Sciences has a consensus price target of $26.41, suggesting a potential upside of 328.76%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Oruka Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Oruka Therapeutics' return on equity of -26.16% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Oruka Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. Oruka Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
WAVE Life Sciences	$42.73M	27.74	-$204.38M	-$1.06	N/A

In the previous week, Oruka Therapeutics had 8 more articles in the media than WAVE Life Sciences. MarketBeat recorded 9 mentions for Oruka Therapeutics and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.50 beat Oruka Therapeutics' score of -0.06 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, suggesting that its stock price is 233% less volatile than the broader market.

Summary

WAVE Life Sciences beats Oruka Therapeutics on 9 of the 15 factors compared between the two stocks.

How does WAVE Life Sciences compare to Veradermics?

WAVE Life Sciences (NASDAQ:WVE) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Veradermics had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Veradermics and 1 mentions for WAVE Life Sciences. Veradermics' average media sentiment score of 0.88 beat WAVE Life Sciences' score of 0.50 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics has lower revenue, but higher earnings than WAVE Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	27.74	-$204.38M	-$1.06	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

WAVE Life Sciences currently has a consensus price target of $26.41, indicating a potential upside of 328.76%. Veradermics has a consensus price target of $114.20, indicating a potential upside of 21.81%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe WAVE Life Sciences is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

89.7% of WAVE Life Sciences shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Veradermics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Veradermics' return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Veradermics	N/A	N/A	N/A

Summary

WAVE Life Sciences beats Veradermics on 6 of the 11 factors compared between the two stocks.

Get WAVE Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WVE vs. The Competition

Export

Metric	WAVE Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.19B	$3.41B	$6.65B	$12.60B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-5.81	19.73	24.75	24.42
Price / Sales	27.74	320.32	529.30	111.09
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	1.99	8.15	10.81	6.60
Net Income	-$204.38M	$23.91M	$3.57B	$337.10M
7 Day Performance	2.67%	2.57%	0.72%	0.83%
1 Month Performance	-3.45%	0.69%	0.41%	2.25%
1 Year Performance	-6.24%	55.09%	29.34%	36.14%

WAVE Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WVE WAVE Life Sciences	2.986 of 5 stars	$6.16 flat	$26.41 +328.8%	-6.2%	$1.19B	$42.73M	N/A	240
ERAS Erasca	2.2677 of 5 stars	$14.05 +0.3%	$20.11 +43.1%	+897.8%	$4.36B	N/A	N/A	120	Trending News Gap Up
TNGX Tango Therapeutics	2.3737 of 5 stars	$30.94 +3.8%	$38.42 +24.2%	+442.1%	$4.31B	$62.38M	N/A	90	Gap Up High Trading Volume
DNTH Dianthus Therapeutics	2.614 of 5 stars	$82.07 +7.4%	$117.82 +43.6%	+389.6%	$4.18B	$2.04M	N/A	80	News Coverage Insider Trade
ORKA Oruka Therapeutics	2.7648 of 5 stars	$69.89 +2.1%	$131.30 +87.9%	+519.3%	$4.13B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WVE) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

WAVE Life Sciences (WVE) Competitors

WVE vs. ERAS, TNGX, DNTH, ORKA, and MANE

How does WAVE Life Sciences compare to Erasca?

Summary

How does WAVE Life Sciences compare to Tango Therapeutics?

Summary

How does WAVE Life Sciences compare to Dianthus Therapeutics?

Summary

How does WAVE Life Sciences compare to Oruka Therapeutics?

Summary

How does WAVE Life Sciences compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

WAVE Life Sciences (WVE) Competitors

WVE vs. ERAS, TNGX, DNTH, ORKA, and MANE

How does WAVE Life Sciences compare to Erasca?

Does the media favor WVE or ERAS?

Which has preferable valuation and earnings, WVE or ERAS?

Which has more risk & volatility, WVE or ERAS?

Is WVE or ERAS more profitable?

Do analysts rate WVE or ERAS?

Do insiders and institutionals believe in WVE or ERAS?

Summary

How does WAVE Life Sciences compare to Tango Therapeutics?

Which has better valuation & earnings, TNGX or WVE?

Does the media refer more to TNGX or WVE?

Which has more risk & volatility, TNGX or WVE?

Is TNGX or WVE more profitable?

Do insiders & institutionals hold more shares of TNGX or WVE?

Do analysts recommend TNGX or WVE?

Summary

How does WAVE Life Sciences compare to Dianthus Therapeutics?

Is DNTH or WVE more profitable?

Which has stronger earnings & valuation, DNTH or WVE?

Which has more volatility and risk, DNTH or WVE?

Do analysts recommend DNTH or WVE?

Do insiders and institutionals believe in DNTH or WVE?

Does the media refer more to DNTH or WVE?

Summary

How does WAVE Life Sciences compare to Oruka Therapeutics?

Do institutionals & insiders have more ownership in ORKA or WVE?

Do analysts recommend ORKA or WVE?

Is ORKA or WVE more profitable?

Which has stronger earnings & valuation, ORKA or WVE?

Does the media prefer ORKA or WVE?

Which has more volatility and risk, ORKA or WVE?

Summary

How does WAVE Life Sciences compare to Veradermics?

Does the media prefer WVE or MANE?

Which has stronger valuation and earnings, WVE or MANE?

Do analysts rate WVE or MANE?

Do institutionals & insiders believe in WVE or MANE?

Is WVE or MANE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools